Skip to content

PRESTIGE: PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort

PREvention of Stent Thrombosis by an Interdisciplinary Global

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01300507
Acronym
PRESTIGE
Enrollment
2000
Registered
2011-02-21
Start date
2011-06-30
Completion date
2018-03-31
Last updated
2013-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Stent Thrombosis

Keywords

stent thrombosis, intra coronary imaging, blood platelet function testing

Brief summary

The PRESTIGE-registry is a joint effort at 9 European heart centers to collect data regarding patients presenting with stent thrombosis in a dedicated database. There will be extensive clinical and procedural characterization, furthermore blood platelet function testing, intracoronary imaging, DNA-sampling and analysis of thrombus aspiration will be performed.

Detailed description

Rationale: Stent Thrombosis (ST) is a serious complication of percutaneous coronary intervention (PCI) with stent implantation. Previous studies have been hampered by small sample size, in particular regarding the number of patients with late and very late ST and patients with DES thrombosis, and by incomplete patient characterisation, particularly concerning intracoronary imaging and blood platelet function data. Objective: to identify novel predictors and to observe clinical outcome after an episode of ST, with the use of state-of-the-art new techniques such as OCT/IVUS, platelet function testing, genetic analysis. Study design: multicenter matched case control study Study population: Cases: all patients presenting with definite ST. Expected number of patients to be included: 2000 Controls: patients undergoing PCI will be matched based on the following criteria: Expected number of patients to be matched: 2000 1. who underwent a PCI for the same indication 2. who underwent a PCI on the same date (±5 days) 3. who underwent a PCI in the same interventional centre Main study parameters/endpoints: clinical, ECG, biochemical, angiographic, procedural, haematological, histopathological, genetic, OCT/IVUS-imaging, and follow-up characteristics Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Prior to PCI, 50 ml of whole blood will be drawn from all patients. Primary PCI for ST will be performed according to institutional best practise. During PCI, performance of Optical Coherence Tomography and/or Intravascular Ultrasound is encouraged. Thrombus aspiration is performed when indicated. During hospitalisation, all patients will be asked to fulfil a questionnaire regarding possible triggering mechanisms that might have provoked the ST. Patients will be asked to visit the patient clinic for platelet function 30 days after the acute phase of the ST. Finally, patients will be contacted for follow-up details.

Interventions

None listed

Sponsors

Deutsches Herzzentrum Muenchen
CollaboratorOTHER
European Union
CollaboratorOTHER
Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients presenting with stent thrombosis

Exclusion criteria

* patients refusing informed consent

Design outcomes

Primary

MeasureTime frame
to identify novel factors responsible for the occurence of stent thrombosis3 years

Countries

Belgium

Contacts

Primary ContactWalter Desmet, MD, PhD
sic@uzleuven.be+32 16 34 24 66
Backup ContactAdnan Kastrati, MD, PhD
Kastrati@dhm.mhn.de+49 (0) 89 1218-4073

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026